Literature DB >> 9266214

Dietary treatment in late-onset acid maltase deficiency.

O A Bodamer1, J V Leonard, D Halliday.   

Abstract

Late-onset acid maltase deficiency or glycogen storage disease type II (GSD II) is a rare disorder of intralysosomal glycogen metabolism, resulting in progressive myopathy that is secondary to increased muscle protein breakdown. Stable isotope studies in the postabsorptive state have confirmed that mean protein breakdown in GSD II is increased by 31% compared to control subjects. 6.86 versus 4.69 g/kg per day, that mean protein balance is reduced is GSD II -1.32 versus -1.06 g/kg per day. Indirect calorimetry has demonstrated an increase in mean resting energy expenditure in GSD II, 41.8 versus 31.2 kcal/kg per day. Compliance following the introduction of a high-protein diet is often poor due to the large quantities of protein necessary and to the high caloric intake with the consequent weight gain. Only 25% of all reported subjects with GSD II showed an improvement of muscle or respiratory function after a high-protein diet. Careful evaluation of the underlying pathophysiological changes in GSD II is necessary to develop more logical and therefore more beneficial forms of dietary treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266214     DOI: 10.1007/pl00014270

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  6 in total

1.  [Diagnosis and differential diagnosis of lysosomal glycogen storage disease].

Authors:  D Fischer; S Paus; R Schröder
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

Review 2.  Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential.

Authors:  Charles R Roe; Fanny Mochel
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

3.  Efficacy of multidisciplinary approach in the treatment of two cases of nonclassical infantile glycogenosis type II.

Authors:  B Bembi; G Ciana; C Martini; A Benettoni; A Gombacci; M Deganuto; M G Pittis
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

4.  Pompe disease diagnosis and management guideline.

Authors:  Priya S Kishnani; Robert D Steiner; Deeksha Bali; Kenneth Berger; Barry J Byrne; Laura E Case; Laura Case; John F Crowley; Steven Downs; R Rodney Howell; Richard M Kravitz; Joanne Mackey; Deborah Marsden; Anna Maria Martins; David S Millington; Marc Nicolino; Gwen O'Grady; Marc C Patterson; David M Rapoport; Alfred Slonim; Carolyn T Spencer; Cynthia J Tifft; Michael S Watson
Journal:  Genet Med       Date:  2006-05       Impact factor: 8.822

5.  Exercise training alone or in combination with high-protein diet in patients with late onset Pompe disease: results of a cross over study.

Authors:  Annalisa Sechi; Lucrezia Zuccarelli; Bruno Grassi; Rita Frangiamore; Ramona De Amicis; Mauro Marzorati; Simone Porcelli; Annarita Tullio; Anna Bacco; Simona Bertoli; Andrea Dardis; Lea Biasutti; Maria Barbara Pasanisi; Grazia Devigili; Bruno Bembi
Journal:  Orphanet J Rare Dis       Date:  2020-06-06       Impact factor: 4.123

6.  Late-Onset Glycogen Storage Disease Type II (Pompe's Disease) with a Novel Mutation: A Malaysian Experience.

Authors:  Hiew Fu Liong; Siti Aishah Abdul Wahab; Yusnita Yakob; Ngu Lock Hock; Wong Kum Thong; Shanthi Viswanathan
Journal:  Case Rep Neurol Med       Date:  2014-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.